Association between influenza vaccination and cardiovascular outcomes in high-risk patients: a meta-analysis.

IMPORTANCE Among nontraditional cardiovascular risk factors, recent influenzalike infection is associated with fatal and nonfatal atherothrombotic events. OBJECTIVES To determine if influenza vaccination is associated with prevention of cardiovascular events. DATA SOURCES AND STUDY SELECTION A systematic review and meta-analysis of MEDLINE (1946-August 2013), EMBASE (1947-August 2013), and the Cochrane Library Central Register of Controlled Trials (inception-August 2013) for randomized clinical trials (RCTs) comparing influenza vaccine vs placebo or control in patients at high risk of cardiovascular disease, reporting cardiovascular outcomes either as efficacy or safety events. DATA EXTRACTION AND SYNTHESIS Two investigators extracted data independently on trial design, baseline characteristics, outcomes, and safety events from published manuscripts and unpublished supplemental data. High-quality studies were considered those that described an appropriate method of randomization, allocation concealment, blinding, and completeness of follow-up. MAIN OUTCOMES AND MEASURES Random-effects Mantel-Haenszel risk ratios (RRs) and 95% CIs were derived for composite cardiovascular events, cardiovascular mortality, all-cause mortality, and individual cardiovascular events. Analyses were stratified by subgroups of patients with and without a history of acute coronary syndrome (ACS) within 1 year of randomization. RESULTS Five published and 1 unpublished randomized clinical trials of 6735 patients (mean age, 67 years; 51.3% women; 36.2% with a cardiac history; mean follow-up time, 7.9 months) were included. Influenza vaccine was associated with a lower risk of composite cardiovascular events (2.9% vs 4.7%; RR, 0.64 [95% CI, 0.48-0.86], P = .003) in published trials. A treatment interaction was detected between patients with (RR, 0.45 [95% CI, 0.32-0.63]) and without (RR, 0.94 [95% CI, 0.55-1.61]) recent ACS (P for interaction = .02). Results were similar with the addition of unpublished data. CONCLUSIONS AND RELEVANCE In a meta-analysis of RCTs, the use of influenza vaccine was associated with a lower risk of major adverse cardiovascular events. The greatest treatment effect was seen among the highest-risk patients with more active coronary disease. A large, adequately powered, multicenter trial is warranted to address these findings and assess individual cardiovascular end points.

[1]  Y. Leo,et al.  Seasonal Human Influenza: Treatment Options , 2014, Current Treatment Options in Infectious Diseases.

[2]  C. Macintyre,et al.  Ischaemic heart disease, influenza and influenza vaccination: a prospective case control study , 2013, Heart.

[3]  T. Talbot,et al.  Influenza prevention update: examining common arguments against influenza vaccination. , 2013, JAMA.

[4]  D. Musher,et al.  Acute pneumonia and the cardiovascular system , 2013, The Lancet.

[5]  C. Bridges,et al.  Recommended Adult Immunization Schedule: United States, 2013* , 2013, Annals of Internal Medicine.

[6]  C. Diazgranados,et al.  High-dose trivalent influenza vaccine compared to standard dose vaccine in elderly adults: safety, immunogenicity and relative efficacy during the 2009-2010 season. , 2013, Vaccine.

[7]  SalimYusuf,et al.  Impact of Sex on Cardiovascular Outcome in Patients at High Cardiovascular Risk , 2012 .

[8]  S. Yusuf,et al.  Influenza Vaccination and Major Adverse Vascular Events in High-Risk Patients , 2012, Circulation.

[9]  K. Ungchusak,et al.  Lessons Learned from Influenza A(H1N1)pdm09 Pandemic Response in Thailand , 2012, Emerging infectious diseases.

[10]  James A Singleton,et al.  Influenza vaccination coverage among adults--National Health Interview Survey, United States, 2008-09 influenza season. , 2012, MMWR supplements.

[11]  S. Roush.  Manual for the surveillance of vaccine-preventable diseases. Chapter 18: Surveillance indicators , 2011 .

[12]  John Spertus,et al.  AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients with Coronary and other Atherosclerotic Vascular Disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation. , 2011, Circulation.

[13]  J. Sterne,et al.  The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials , 2011, BMJ : British Medical Journal.

[14]  J. Ioannidis,et al.  Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials , 2011, BMJ : British Medical Journal.

[15]  Krishnan Bhaskaran,et al.  Circulating influenza virus, climatic factors, and acute myocardial infarction: a time series study in England and Wales and Hong Kong. , 2011, The Journal of infectious diseases.

[16]  W. Gruber,et al.  A prospective, randomized, open-label trial comparing the safety and efficacy of trivalent live attenuated and inactivated influenza vaccines in adults 60 years of age and older. , 2011, Vaccine.

[17]  C. Cannon,et al.  Myocardial infarction vaccine? Evidence supporting the influenza vaccine for secondary prevention. , 2011, European heart journal.

[18]  M. Schwaninger,et al.  Influenza Virus Infection Aggravates Stroke Outcome , 2011, Stroke.

[19]  W. Wongcharoen,et al.  Influenza vaccination reduces cardiovascular events in patients with acute coronary syndrome. , 2011, European heart journal.

[20]  Seemant Chaturvedi,et al.  Guidelines for the Primary Prevention of Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association , 2011, Stroke.

[21]  J. Nguyen-Van-Tam,et al.  Evaluation of inter-pandemic influenza vaccine effectiveness during eight consecutive winter seasons in England and Wales in patients with cardiovascular risk factors. , 2010, Journal of infection and public health.

[22]  I. Hung,et al.  Prevention of acute myocardial infarction and stroke among elderly persons by dual pneumococcal and influenza vaccination: a prospective cohort study. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[23]  C. Coupland,et al.  Influenza vaccination, pneumococcal vaccination and risk of acute myocardial infarction: matched case–control study , 2010, Canadian Medical Association Journal.

[24]  C. Kȩpka,et al.  Original paper The protective effect of influenza vaccination on the clinical course of coronary disease in patients with acute coronary syndromes treated by primary PCI – a report from FLUCAD study , 2010 .

[25]  P. Grossfeld,et al.  Fulminant myocarditis associated with pandemic H1N1 influenza A virus in children. , 2010, Journal of the American College of Cardiology.

[26]  W. Gruber,et al.  Efficacy and safety of a live attenuated influenza vaccine in adults 60 years of age and older. , 2009, Vaccine.

[27]  Liam Smeeth,et al.  Influenza as a trigger for acute myocardial infarction or death from cardiovascular disease: a systematic review. , 2009, The Lancet. Infectious diseases.

[28]  D. Moher,et al.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement , 2009, BMJ : British Medical Journal.

[29]  A. Falsey,et al.  Randomized, double-blind controlled phase 3 trial comparing the immunogenicity of high-dose and standard-dose influenza vaccine in adults 65 years of age and older. , 2009, The Journal of infectious diseases.

[30]  S. Cutler.  Myths, legends and realities of relapsing fever borreliosis. , 2009, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[31]  T. Marrie,et al.  Mortality reduction with influenza vaccine in patients with pneumonia outside "flu" season: pleiotropic benefits or residual confounding? , 2008, American journal of respiratory and critical care medicine.

[32]  M. Levi,et al.  Influenza vaccines for preventing coronary heart disease. , 2008, The Cochrane database of systematic reviews.

[33]  C. Kȩpka,et al.  Influenza vaccination in secondary prevention from coronary ischaemic events in coronary artery disease: FLUCAD study. , 2008, European heart journal.

[34]  J. Oxford,et al.  Flu: Effect of Vaccine in Elderly Care Home Residents: A Randomized Trial , 2007, Journal of the American Geriatrics Society.

[35]  L. Rosella,et al.  Trends in influenza vaccination in Canada, 1996/1997 to 2005. , 2007, Health reports.

[36]  K. Nichol,et al.  Effectiveness of influenza vaccine in the community-dwelling elderly. , 2007, The New England journal of medicine.

[37]  J. Beyene,et al.  Inclusion of zero total event trials in meta-analyses maintains analytic consistency and incorporates all available data , 2007, BMC medical research methodology.

[38]  H. Krumholz,et al.  Influenza Vaccination as Secondary Prevention for Cardiovascular Disease: A Science Advisory From the American Heart Association/American College of Cardiology , 2006, Circulation.

[39]  M. Pfeffer,et al.  AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update endorsed by the National Heart, Lung, and Blood Institute. , 2006, Journal of the American College of Cardiology.

[40]  M. Pfeffer,et al.  AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. , 2006, Circulation.

[41]  J. Nauta,et al.  Clinical experience with inactivated, virosomal influenza vaccine. , 2005, Vaccine.

[42]  A. Grau,et al.  Influenza Vaccination Is Associated With a Reduced Risk of Stroke , 2005, Stroke.

[43]  A. Mokdad,et al.  Examining the coverage of influenza vaccination among people with cardiovascular disease in the United States. , 2005, American heart journal.

[44]  R. Hubbard,et al.  Risk of myocardial infarction and stroke after acute infection or vaccination. , 2004, The New England journal of medicine.

[45]  E. Gurfinkel,et al.  Flu vaccination in acute coronary syndromes and planned percutaneous coronary interventions (FLUVACS) Study. , 2004, European heart journal.

[46]  John Mullooly,et al.  Influenza vaccination and reduction in hospitalizations for cardiac disease and stroke among the elderly. , 2003, The New England journal of medicine.

[47]  Douglas G Altman,et al.  Interaction revisited: the difference between two estimates , 2003, BMJ : British Medical Journal.

[48]  S. Thompson,et al.  Quantifying heterogeneity in a meta‐analysis , 2002, Statistics in medicine.

[49]  E. Gurfinkel,et al.  Influenza Vaccine Pilot Study in Acute Coronary Syndromes and Planned Percutaneous Coronary Interventions: The FLU Vaccination Acute Coronary Syndromes (FLUVACS) Study , 2002, Circulation.

[50]  D. Grabli,et al.  Association Between Influenza Vaccination and Reduced Risk of Brain Infarction , 2002, Stroke.

[51]  D. Rose,et al.  Study of community acquired pneumonia aetiology (SCAPA) in adults admitted to hospital: implications for management guidelines , 2001, Thorax.

[52]  M. Naghavi,et al.  Association of Influenza Vaccination and Reduced Risk of Recurrent Myocardial Infarction , 2000, Circulation.

[53]  T. Raghunathan,et al.  Influenza vaccination and the risk of primary cardiac arrest. , 2000, American journal of epidemiology.

[54]  L. Jackson,et al.  Safety of a trivalent live attenuated intranasal influenza vaccine, FluMist, administered in addition to parenteral trivalent inactivated influenza vaccine to seniors with chronic medical conditions. , 1999, Vaccine.

[55]  A R Jadad,et al.  Assessing the quality of reports of randomized clinical trials: is blinding necessary? , 1996, Controlled clinical trials.

[56]  K. Nichol,et al.  The efficacy and cost effectiveness of vaccination against influenza among elderly persons living in the community. , 1994, The New England journal of medicine.

[57]  N. Laird,et al.  Meta-analysis in clinical trials. , 1986, Controlled clinical trials.

[58]  D. Bainton,et al.  Influenza and ischaemic heart disease--a possible trigger for acute myocardial infarction? , 1978, International journal of epidemiology.

[59]  M. Ryan,et al.  Guidelines for the primary prevention of stroke : a guideline for health care professionals from the American Heart Association / American Stroke Association , 2013 .

[60]  C. Bias.  The Cochrane Collaboration's tool for assessing risk of bias in randomised trials , 2011 .

[61]  Rabi Bhattacharya,et al.  Continuity Correction , 2011, International Encyclopedia of Statistical Science.

[62]  Jodie L. Conyers,et al.  Factors contributing to suboptimal vaccination against influenza: results of a nationwide telephone survey of persons with cardiovascular disease. , 2009, Texas Heart Institute journal.

[63]  M. Roizen.  Influenza epidemics and acute respiratory disease activity are associated with a surge in autopsy-confirmed coronary heart disease death: results from 8 years of autopsies in 34 892 subjects , 2008 .

[64]  Imran Awan,et al.  Influenza and cardiovascular disease: is there a causal relationship? , 2004, Texas Heart Institute journal.

[65]  C. Bridges,et al.  Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). , 2000, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[66]  G. Dinant,et al.  The efficacy of influenza vaccination in elderly individuals. A randomized double-blind placebo-controlled trial. , 1994, JAMA.